Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,275 | 30 | 57.8% |
| Consulting Fee | $25,538 | 7 | 33.3% |
| Travel and Lodging | $3,396 | 16 | 4.4% |
| Unspecified | $2,138 | 1 | 2.8% |
| Food and Beverage | $1,238 | 37 | 1.6% |
| Education | $57.50 | 12 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PTC Therapeutics, Inc. | $50,189 | 58 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $16,348 | 8 | $0 (2023) |
| ACADIA Pharmaceuticals Inc | $3,844 | 5 | $0 (2024) |
| Merz Pharmaceuticals, LLC | $3,588 | 1 | $0 (2021) |
| Retrophin, Inc. | $2,160 | 6 | $0 (2019) |
| Medtronic USA, Inc. | $166.42 | 3 | $0 (2017) |
| Marinus Pharmaceuticals, Inc. | $102.67 | 3 | $0 (2023) |
| UCB, Inc. | $75.35 | 3 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $73.01 | 5 | $0 (2019) |
| EISAI INC. | $33.75 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,963 | 7 | PTC Therapeutics, Inc. ($7,950) |
| 2023 | $35,361 | 49 | PTC Therapeutics, Inc. ($16,822) |
| 2022 | $11,051 | 12 | PTC Therapeutics, Inc. ($9,175) |
| 2021 | $18,813 | 13 | PTC Therapeutics, Inc. ($15,225) |
| 2020 | $3.58 | 4 | Travere Therapeutics, Inc. ($3.58) |
| 2019 | $81.43 | 8 | Sunovion Pharmaceuticals Inc. ($40.11) |
| 2018 | $1,031 | 3 | PTC Therapeutics, Inc. ($1,016) |
| 2017 | $2,337 | 7 | Retrophin, Inc. ($2,138) |
All Payment Transactions
103 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/21/2024 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 10/21/2024 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 05/30/2024 | ACADIA Pharmaceuticals Inc | DAYBUE (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: RETT SYNDROME | ||||||
| 05/14/2024 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 04/10/2024 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 04/09/2024 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 02/09/2024 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $450.00 | General |
| 11/18/2023 | ACADIA Pharmaceuticals Inc | DAYBUE (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: RETT SYNDROME | ||||||
| 08/09/2023 | PTC Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 08/04/2023 | ORPHALAN INC | CUVRIOR (Drug) | Food and Beverage | In-kind items and services | $27.30 | General |
| Category: Hepatology | ||||||
| 07/14/2023 | Marinus Pharmaceuticals, Inc. | ZTALMY (Drug) | Food and Beverage | In-kind items and services | $38.87 | General |
| Category: SEIZURE DISORDERS | ||||||
| 07/12/2023 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| 07/08/2023 | ACADIA Pharmaceuticals Inc | DAYBUE (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: RETT SYNDROME | ||||||
| 06/16/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: UPLIZNA | ||||||
| 06/09/2023 | ACADIA Pharmaceuticals Inc | DAYBUE (Drug) | Food and Beverage | In-kind items and services | $9.09 | General |
| Category: RETT SYNDROME | ||||||
| 05/26/2023 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $30.77 | General |
| Category: Neurology | ||||||
| 05/12/2023 | Marinus Pharmaceuticals, Inc. | ZTALMY (Drug) | Food and Beverage | In-kind items and services | $34.40 | General |
| Category: SEIZURE DISORDERS | ||||||
| 05/05/2023 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| 04/22/2023 | PTC Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $85.73 | General |
| 04/22/2023 | PTC Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $39.21 | General |
| 04/22/2023 | PTC Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $34.99 | General |
| 04/22/2023 | PTC Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $30.19 | General |
| 04/22/2023 | PTC Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $10.51 | General |
| 04/21/2023 | PTC Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $121.00 | General |
| 04/21/2023 | PTC Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $55.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| FORT Study | Retrophin, Inc. | $2,138 | 1 |
About Dr. Michael Kruer, M.D
Dr. Michael Kruer, M.D is a Neurodevelopmental Disabilities healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1366640468.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Kruer, M.D has received a total of $76,642 in payments from pharmaceutical and medical device companies, with $7,963 received in 2024. These payments were reported across 103 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($44,275).
Practice Information
- Specialty Neurodevelopmental Disabilities
- Location Phoenix, AZ
- Active Since 07/10/2007
- Last Updated 10/24/2019
- Taxonomy Code 2084P0005X
- Entity Type Individual
- NPI Number 1366640468
Products in Payments
- Xeomin (Biological) $3,588
- (810) Chenodal (Drug) $2,138
- DAYBUE (Drug) $2,044
- SYNCHROMED (Device) $166.42
- EMFLAZA (Drug) $137.67
- ZTALMY (Drug) $102.67
- Nayzilam (Drug) $75.35
- APTIOM (Drug) $73.01
- Fycompa (Drug) $33.75
- CUVRIOR (Drug) $27.30
- (820) Cholbam (Drug) $25.84
- Emflaza (Drug) $16.45
- VALTOCO (Drug) $15.57
- UPLIZNA (Drug) $14.86
- Cholbam (Drug) $1.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurodevelopmental Disabilities Doctors in Phoenix
Dr. Tamara Zach, M.d, M.D
Neurodevelopmental Disabilities — Payments: $4,470
Dr. Mary Allare, Md, MD
Neurodevelopmental Disabilities — Payments: $55.34
Dr. David Hirsch, M.d, M.D
Neurodevelopmental Disabilities — Payments: $14.33
Benjmamin Carlson, Pta, PTA
Neurodevelopmental Disabilities